|Bid||9.95 x 100|
|Ask||12.95 x 1400|
|Day's range||10.25 - 10.55|
|52-week range||9.30 - 17.55|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.06|
Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.
Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.
Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.
On a per-share basis, the Rockville, Maryland-based company said it had profit of 19 cents. Earnings, adjusted for one-time gains and costs, came to 27 cents per share. The biopharmaceutical company posted ...
DGAP-News: Sucampo Pharmaceuticals, Inc.03.04.2017 / 12:30 The issuer is solely responsible for the content of this announcement.Transaction Valued at $200 Million UpfrontDiversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1)Increases Company Focus on Specialized Diseases with High Unmet NeedLeverages Focus on Orphan and Pediatric DiseasesExpected to be Accretive to Earnings Beginning in 2019Shareholders and Investors of Sucampo and Vtesse to Establish Foundation to Support Research Related to NPC DiseaseCompany to Host Conference Call Today at 8:30 a.m. ...